Optimer, Astellas deal

Optimer granted Astellas exclusive rights in Japan to develop and commercialize antibiotic fidaxomicin. Optimer will receive $20 million up front and is eligible for up to an additional $70 million in milestones. Optimer could also receive payments representing a double-digit percent of net sales in Japan. ...